Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) does about 1.25M shares in volume on a normal day but saw 1100060 shares change hands in the recent trading day. The company now has a market cap of 9.92M USD. Its current market price is $1.25, marking an increase of 0.81% compared to the previous close of $1.24. The 52 week high reached by this stock is $8.09 whilst the lowest price level in 52 weeks is $0.72.
The consensus objective for the share price is $6.00, suggesting that the stock has a potential upside of 79.17% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 04, 2021 when Maxim Group upgraded the stock to “Buy” and issued a price target of $12. Maxim Group reiterated its price target at $5-$6.
The current price level is 7.16%, 12.96%, and -35.89% away from its SMA20, SMA50, and SMA200 respectively, with the BCLI price moving below the 50-day SMA on current market day. Brainstorm Cell Therapeutics, Inc (BCLI) stock is up 15.74% over the week and 5.93% over the past month. Its price is -44.93% year-to-date and -79.83% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.33 and -1.6 for whole year.
To reach the target analysts have set, the stock logically needs to grow 79.17 percent from here.
Outstanding shares total 7.91M with insiders holding 15.98% of the shares and institutional holders owning 12.89% of the company’s common stock. The beta has a value of 0.22.
